Positive data from Bristol Myers in multiple myeloma and Pfizer in lung cancer unveiled at ASCO

At the American Society of Clinical Oncology (ASCO) meeting, Bristol Myers Squibb presented early-stage results that showed a favorable response in a multiple myeloma trial. The data suggest the investigational therapy may improve outcomes for patients with this blood cancer.

Pfizer also shared encouraging findings from a lung cancer study, reporting a positive signal in its experimental treatment. The results add to the growing pipeline of oncology candidates being evaluated at the conference.

Both companies highlighted the potential of these programs to address unmet medical needs, and analysts will be watching for further data as the trials progress.

The coverage was provided by STAT+ reporters Adam Feuerstein, Matthew Herper and Angus Chen as part of their ASCO roundup.